Please login to the form below

Not currently logged in
Email:
Password:

Kisplyx

This page shows the latest Kisplyx news and features for those working in and with pharma, biotech and healthcare.

NICE gives green light to Ipsen's Cabometyx

NICE gives green light to Ipsen's Cabometyx

Meanwhile, NICE is in the process of assessing Eisai’s Kisplyx (lenvatinib) - approved by European regulators in 2016 as a second-line combination treatment for advanced RCC, guidance from England’s

Latest news

  • Eisai wins EU licence for kidney cancer drug Kisplyx Eisai wins EU licence for kidney cancer drug Kisplyx

    Eisai wins EU licence for kidney cancer drug Kisplyx. Approved as a second-line combination treatment for advanced RCC. ... The European Commission has approved Kisplyx (lenvatinib) for the treatment of adults with advanced renal cell carcinoma (RCC)

  • HIV prevention pill heads July CHMP recommendations HIV prevention pill heads July CHMP recommendations

    HIV prevention pill heads July CHMP recommendations. Gilead’ s Truvada given positive opinion alongside Ipsen Pharma’ s Cabometyx and Eisai’ s Kisplyx. ... The panel also recommended approval of two targeted kidney cancer medicines - Ipsen Pharma's

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics